TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01237405
Drug: 99mTc-EC20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at \~1 minute) SPECT/CT of both knees; a late phase (at \~60 minutes) SPECT/CT image of both knees; and a late phase (at \~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
Study: NCT02726295
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00016302
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT and orally
Study: NCT00016302
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00016302
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00016302
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally
Study: NCT00016302
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01554852
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
Study: NCT01968668
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg BAY94-8862 tablet once daily in the morning
Study: NCT01968668
Drug: BAY94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg BAY94-8862 tablet once daily in the morning
Study: NCT01968668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily in the morning
Study: NCT01968668
Drug: BAY 94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg BAY 94-8862 tablet once daily in the morning
Study: NCT01968668
Drug: BAY 94-8862
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg BAY 94-8862 tablet once daily in the morning
Study: NCT01554852
Drug: Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
Study: NCT01554852
Drug: Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1 \& 2, 8 \& 9, 15 \& 16 - carfilzomib 20\*/36 mg/m2\*\* IV (\*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; \*\*carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 \& 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
Study: NCT01554852
Drug: Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1 \& 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
Study: NCT01554852
Drug: Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 \& 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
Study: NCT01554852
Drug: Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1, 4, 8 \& 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 \& 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
Study: NCT02536352
Drug: Prenatal vitamin-mineral containing 3 mg fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
Study: NCT00088101
Drug: STA-5312
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04556825
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the arthroscopic operation was completed, a local normal saline injection with same ml was performed
Study: NCT00377806
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00060255
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv
Study: NCT00728182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
Study: NCT02232633
Drug: BBI503
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02808026
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-3150 2.5 to 5mg, orally, once daily after breakfast
Study: NCT05264584
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.
Study: NCT01933425
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03849456
Drug: GWP42006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
Study: NCT02366130
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
Study: NCT03495323
Drug: LY3300054
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
Study: NCT00425854
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose once daily
Study: NCT01386177
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules identical to MDMA or doxazosin
Study: NCT00114478
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01951027
Drug: GX-G3 12.5 μg/kg or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC injection
Study: NCT01951027
Drug: GX-G3 25 μg/kg or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC injection
Study: NCT01951027
Drug: GX-G3 50 μg/kg or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC injection
Study: NCT01951027
Drug: GX-G3 100 μg/kg or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SC injection
Study: NCT03921541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
Study: NCT04618965
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.
Study: NCT03150797
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin
Study: NCT03150797
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03993431
Drug: Bio-active cement
Normalized name: citric acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A cement used for crown cementation, specially recommended for pediatric esthetic crowns
Study: NCT03993431
Drug: Packable glass ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
Study: NCT02264041
Drug: Cilobradine, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264041
Drug: Cilobradine, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05862441
Drug: AV2-SA2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV2 is a combination of FDA GRAS-label approved organic compounds (natural essential oils: carvone, eugenol, geraniol, and nerolidol) that is postulated to be able to prevent viral entry and proliferation by deactivating the infectious virions before they enter the cell. Salicylic acid (SA) formulations are the most commonly used preparations in the treatment of warts. SA is an organic acid that destroys epidermal cells and softens hyperkeratotic epidermis. Implementation of AV2-SA combination therapy would ensure permanent lesion clearance by on the one hand inactivation of HPV by AV2, and on the other hand elimination of the lesion by SA treatment.
Study: NCT02194088
Drug: Diclofenac and Atropine combination drug
Normalized name: pralidoxime and atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac will be associated with a small dose of atropine 1.2mg
Study: NCT02194088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each capsule of active medication, a capsule of placebo will be provided, identical looking.
Study: NCT02170012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily dosing for 14 days
Study: NCT05406999
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
Study: NCT05406999
Drug: Prednisolone tablets
Normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg once daily, orally.
Study: NCT01436292
Drug: 5% human albumin solution (HAS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; \< 10 gr/L: 150 g of 5% HAS.
Study: NCT01814332
Drug: GSK561679
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK561679, oral administration, 350mg/day, 6 week administration
Study: NCT01814332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo compound treatment for comparison with IP
Study: NCT03569007
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: enteric-coated beads in gelatin capsules
Study: NCT00001857
Drug: BG9588
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02172742
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 2-093 1200 mg once-daily
Study: NCT02172742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT03099863
Drug: Cystoscopic Fluid containing Neosporin G. U. Irrigant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
Study: NCT03099863
Drug: Cystoscopic Fluid/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline cystoscopic fluid
Study: NCT00580294
Drug: Oxymorphone
Normalized name: Oxymorphone
DrugBank: Oxymorphone (DB01192)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV PO
Study: NCT01491932
Drug: AFQ056
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFQ056 will be supplied as oral capsules.
Study: NCT00043680
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02196558
Drug: E6011
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005898
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03622931
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT03622931
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02618395
Drug: SPARC001A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02618395
Drug: SPARC001B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02618395
Drug: Reference001 - Hydrocodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-acetaminophen
Study: NCT01721330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 6 weeks
Study: NCT00326456
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 gieven intravenously on day 1 every 3 weeks
Study: NCT00165347
Drug: PTK787/ZK222584
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02235012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHLORURE DE SODIUM 0,9 % MACOPHARMA :~* Initial rapid infusion of 0,23 mg/kg~* Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~* Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min
Study: NCT02106559
Drug: photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo PDT
Study: NCT02636322
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02636322
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02326090
Drug: cis-UCA ophthalmic solution 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02326090
Drug: cis-UCA ophthalmic solution 2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02326090
Drug: Placebo ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00513864
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one time dose - 2mg/kg PO
Study: NCT00001082
Drug: Levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg tablet taken orally daily
Study: NCT02618187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02618187
Drug: Placebo Pre-Treat
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03488485
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAAs given in patients with viremic chronic hepatitis C
Study: NCT02993432
Drug: prostaglandin of the clinician's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
Study: NCT00279513
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00393146
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug
Study: NCT01981928
Drug: ASP7962
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01981928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01444170
Drug: placebo sugar pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02390375
Drug: DW-0929
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/10mg
Study: NCT02390375
Drug: DW-0929
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/10mg
Study: NCT02390375
Drug: DW-0929
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/10mg
Study: NCT02390375
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg F/U study: DW-0929 5/10mg
Study: NCT02390375
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg F/U study: DW-0929 10/10mg
Study: NCT02390375
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg F/U study: DW-0929 20/10mg
Study: NCT00372320
Drug: AdhAQP1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03055507
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Addition of ibuprofen to standard pain regimen.
Study: NCT03055507
Drug: Acetaminophen 650 mg
Normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic provided post-operatively to patients undergoing sinus surgery
Study: NCT02369250
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin, is a statin group of drug.
Study: NCT02315196
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00699166
Drug: DNK333
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg and 100 mg oral doses, each taken twice daily
Study: NCT01783236
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg IV Ofirmev given every six hours for a total of four doses.
Study: NCT01783236
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
Study: NCT03934307
Drug: ALN-AGT01-Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
Study: NCT04193527
Drug: DaTSCAN™ Ioflupane (123I) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.
Study: NCT04551924
Drug: HR18034
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
Study: NCT00887588
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, 100 mg and 200 mg tablets
Study: NCT00887588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to LCZ696 and Valsartan
Study: NCT03335566
Drug: Sonazoid™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
Study: NCT03335566
Drug: SonoVue®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose of SonoVue® 2.4 mL as I.V. injection.
Study: NCT03721965
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
Study: NCT03568071
Drug: MOR 106
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
Study: NCT03568071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
Study: NCT04488094
Drug: [18F]FSPG
Approvals — FDA: no, EMA: no, PMDA: no
Description: A radioactive dose of 200 MBq of the study drug with a total quantity of ≤ 100 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 60-75 min after the administration of \[18F\]FSPG.
Study: NCT00291226
Drug: Glycine
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine 0.4 g/kg bid
Study: NCT00291226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00557102
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00557102
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00127933
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 825mg/m2 po bid on days 1-14 of each 3 week cycle
Study: NCT03753477
Drug: Sevikar and Crestor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
Study: NCT00498485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
Study: NCT00066937
Drug: Benztropine Oral Product
Normalized name: benztropine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.